To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Dronabinol does not cause metabolic disturbances in managing chronic neuropathy pain

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
October 2018

Dronabinol does not cause metabolic disturbances in managing chronic neuropathy pain

Vol: 7| Issue: 10| Number:43| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

A 4-week pilot study with the cannabinoid receptor agonist dronabinol and its effect on metabolic parameters in a randomized trial

Clin Ther. 2015 Oct 1;37(10):2267-74. doi: 10.1016/j.clinthera.2015.07.023

Contributing Authors:
L Bayman J Valestin A Rizvi-Toner R Schey ZW Reichenbach J Sloan

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

13 patients diagnosed with non-cardiac chest pain were randomly assigned to orally consume twice a day for 4 weeks either 5mg dronabinol capsules or placebo capsules. Metabolic parameters such as body mass index, various cholesterol levels, triglyceride level, plasma glucose level, insulin and leptin level, and high-sensitivity C-reactive protein level were assessed at the beginning and end of the...

Join the Conversation

Please Login or Join to leave comments.